Investigating the role of suPAR in kidney fibrosis
suPAR and renal fibrosis
This study is looking at how a protein called suPAR might harm the kidneys in people with chronic kidney disease (CKD), with the hope of finding new ways to prevent or treat kidney damage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-10829902 on NIH RePORTER |
What this research studies
This research focuses on understanding how a protein called suPAR contributes to kidney damage and fibrosis in chronic kidney disease (CKD). By examining the interactions between suPAR and specific receptors in kidney cells, the study aims to uncover the mechanisms that lead to kidney injury. The research involves laboratory experiments that analyze how elevated levels of suPAR affect kidney function and structure, particularly in different parts of the nephron. The ultimate goal is to identify potential therapeutic targets that could help prevent or treat kidney fibrosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic kidney disease, particularly those experiencing kidney fibrosis.
Not a fit: Patients with acute kidney injury or those without chronic kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent kidney damage in patients with chronic kidney disease.
How similar studies have performed: Previous research has shown promising results in understanding the role of suPAR in kidney diseases, indicating that this approach has potential for significant advancements.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Wei, David Changli — University of Texas Med Br Galveston
- Study coordinator: Wei, David Changli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.